• $3.2 million revenue driven by Remplir's growing US penetration
• Strong financial position with $48 million cash reserves
• Remplir approved for US Department of Defense hospital network

Orthocell Limited (ASX: OCC) has released its Quarterly Report for the quarter ended 31 March 2026, highlighting continued strong progress in the commercialization of its Remplir nerve repair product, particularly in the United States. The company reported quarterly revenue of $3.2 million, a 45% increase on the prior corresponding period, driven primarily by Remplir's growing penetration in existing markets and the commencement of material sales from the US. March quarter revenue was in line with the prior quarter, with US sales reaching $300,000, including $170,000 in Remplir sales, providing early evidence of a potential revenue inflection point within the US$1.6 billion addressable market. Orthocell maintains a strong financial position with robust cash reserves of $48 million as at 31 March 2026 and is well-positioned for continued commercial expansion. The company also reported demonstrable progress in the commercialization of Remplir, including the expansion of its US distributor network to cover 16+ states and approximately 40% of the US population, the completion of 6 major medical education events, and the securing of 32 Value Analysis Committee approvals providing access to over 115 hospitals. Subsequent to the end of the quarter, Orthocell secured approval for Remplir to be used across the US Department of Defense hospital networks, comprising 221 medical centres, and has already completed the first surgical case in this system. The company is also making progress in other key markets, including Canada and the UK/EU.

Orthocell reported quarterly revenue of $3.2 million, representing a 45% increase on the prior corresponding period. Year-to-date (Q1-Q3 FY26) revenue of $9.4 million represents a 45% increase on the prior corresponding period.

With a very strong cash position and expanding global footprint, Orthocell is well positioned to continue executing on its commercial strategy and drive further adoption of Remplir across key markets.